Duality Biotherapeutics, Inc. (HKG:9606)

Duality Biotherapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023
Revenue	2,170	1,941	1,787
Revenue Growth (YoY)	-	8.66%	-
Cost of Revenue	1,365	1,157	427.66
Gross Profit	805.86	784.67	1,359
Selling, General & Admin	210.96	158.69	62.57
Research & Development	808.53	815.38	559
Other Operating Expenses	-2.24	-2.36	1.06
Operating Expenses	1,017	971.71	622.62
Operating Income	-211.4	-187.04	736.27
Interest Expense	-0.69	-0.25	-0.19
Interest & Investment Income	61.26	48.11	34.48
Currency Exchange Gain (Loss)	-4.93	12.27	41.94
Other Non Operating Income (Expenses)	-2,672	-873.42	-1,018
EBT Excluding Unusual Items	-2,828	-1,000	-205.4
Asset Writedown	-	-21.35	-
Other Unusual Items	7.12	7.12	3.15
Pretax Income	-2,821	-1,015	-202.25
Income Tax Expense	10.3	35.89	155.26
Net Income	-2,831	-1,050	-357.51
Net Income to Common	-2,831	-1,050	-357.51
Shares Outstanding (Basic)	25	8	8
Shares Outstanding (Diluted)	25	8	8
EPS (Basic)	-113.91	-131.30	-44.69
EPS (Diluted)	-113.91	-131.30	-44.69
Free Cash Flow	693.08	281.7	805.05
Free Cash Flow Per Share	27.89	35.21	100.63
Gross Margin	37.13%	40.42%	76.06%
Operating Margin	-9.74%	-9.63%	41.21%
Profit Margin	-130.43%	-54.11%	-20.01%
Free Cash Flow Margin	31.93%	14.51%	45.06%
EBITDA	-205.78	-183.72	737.75
EBITDA Margin	-9.48%	-9.46%	41.30%
D&A For EBITDA	5.62	3.32	1.48
EBIT	-211.4	-187.04	736.27
EBIT Margin	-9.74%	-9.63%	41.21%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.